title: Treatment of rheumatic diseases and hepatitis B virus coinfection.
abstract: We often encounter rheumatological patients coinfected with hepatitis B in daily practice. In this paper, we will discuss the basic characteristics of the virus of hepatitis B, course of infection, the safety of rituximab, tocilizumab, abatacept treatment and therapeutic recommendations in management of patients with rheumatic diseases.
authors.affiliation: Institute of Rheumatology, Connective Tissue Department, 1 Spartanska Street, Warsaw, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Felis-Giemza
authors.forename: Marzena
authors.initials: M
authors.lastname: Olesińska
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Świerkocka
authors.forename: Ewa
authors.initials: E
authors.lastname: Więsik-Szewczyk
authors.forename: Ewa
authors.initials: E
authors.lastname: Haładyj
mesh_terms: D000069594:Abatacept / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D006513:Hepatitis B e Antigens / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000150:complications / Q000188:drug therapy*; D000069283:Rituximab / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D007166:Immunosuppressive Agents; D000069283:Rituximab; D000069594:Abatacept; C502936:tocilizumab